Home

Deck

BAWAG Group · BG · Vienna

BAWAG is an Austrian commercial bank that earns roughly twice the European bank median return on equity through low-cost retail deposits, a single-tech platform, and a 14-deal acquisition machine focused on developed-market lending.

$178
Price
$13.7B
Market cap
$85B
Total assets
$1.0B
Net profit FY25
Listed October 2017 at $57; range-bound through 2022, then compounded to a $180 all-time high in April 2026 — roughly 3.3× from IPO with dividends added.
2 · The tension

Three years of 27% RoTCE — structural baseline or cyclical peak?

  • The premium. At $178, BAWAG trades at 3.0× tangible book on FY25 RoTCE 26.9% — the entire $120+ per-share premium above book is a bet that mid-20s RoTCE is the new normal, not the cyclical top.
  • Management's own floor. Every CEO letter since 2022 anchors the through-cycle target at 'above 20%'; three years of 25%+ delivery through negative rates, ECB peak, and ECB cuts has never moved that floor higher.
  • The peer math. AIB at 22% RoTCE prints 1.5× tangible book; a 5-point compression toward management's own anchor pulls BAWAG toward the EU peer median 1.4× — implying a price near $106.
The 700-basis-point gap between the 27% spot and the 20% floor is the valuation gap.
3 · Money picture

Best-in-class unit economics — engineered for spread, not fees.

$1.0B
Net profit FY25 +13% YoY
26.9%
Return on tangible equity ~2× EU median
36.1%
Cost-income ratio EU median ~55%
0.8%
NPL ratio half EU average

The mechanism is mechanical. Customer deposits of $73B fund a $60B loan book at 122% coverage, so cumulative deposit beta sat at just 35% as the ECB cut from 4% toward 2% — Q1 2026 NIM rose to 3.45%. Fee mix is only 17% of operating income (KBC 35%, ING 30%), so when replicating-portfolio yields roll off through 2026–2027 there is no insurance or asset-management buffer to absorb compression.

4 · The PTSB swing

A $1.86B Irish acquisition that grows the bank 40% — and tests a 14-deal track record.

  • The deal. Recommended cash offer for Permanent TSB announced 14 April 2026 at $3.42/share ($1.86B). Closes Q4 2026 / Q1 2027. Balance sheet expands ~40%; consumes ~450bps of CET1; H1 2026 dividend paused to self-fund.
  • The price fight. Sretaw, a 7.2% PTSB shareholder, called the offer 'materially too low'; Goodbody called it 'extremely disappointing'. Roughly $425–460M of the headline EPS accretion is one-off day-one badwill, not operating synergy.
  • The structural difference. The prior 14 deals (Knab, Barclays cards, Südwestbank) absorbed orphan books that had no defending #1. PTSB enters as Ireland's #3 against an AIB/BoI duopoly that controls ~50% of new mortgages — and a public 98-branch commitment caps the cost lever.
The largest deal ever attempted, into the one market on the file BAWAG cannot buy quietly.
5 · The next nine months

Three dated events resolve the entire bull-bear gap.

  • 22 July 2026 — H1 results. First clean post-Knab/Barclays comparable. RoTCE at or above 25% with NIM at or above 3.20% defends the 3.0× book multiple; a slip toward 22% on a clean base is the bear's primary trigger.
  • Q2–Q3 2026 — PTSB scheme document and EGM. The financial-assumptions section quantifies day-one badwill and synergy timing; Sretaw's 7.2% bloc is the dissent risk on the vote.
  • Q4 2026 / Q1 2027 — PTSB closing. Day-1 pro-forma cost-income ratio below 42% confirms the integration playbook works against a duopoly; above 45% breaks the >$295M PBT-by-2028 underwriting case.
Sell-side is crowded long: of the 11 currently-rated brokers on the BAWAG IR consensus list, 10 are at Buy / Outperform / Overweight (average target $206). Erste's $171 Hold is the sole below-market call.
6 · Bull & Bear

Lean long, wait for the post-acquisition clean print.

  • For. Q1 2026 NIM rose to 3.45% as the ECB cut toward 2% — cumulative deposit beta of 35% with rates falling shows the franchise sets pricing, not the market.
  • For. CEO Abuzaakouk bought $1.4M of stock at $173.50 on 29 April 2026 — eight days after Q1 results; zero insider sales since the 2017 IPO; Mgmt Board owns 4.6% (~$630M).
  • Against. The 3.0× tangible-book multiple leaves no margin if RoTCE compresses — management's own through-cycle floor has stayed 'above 20%' since 2022, not 27%, despite three years of delivery above it.
  • Against. PTSB attacks a defended Irish duopoly unlike the prior 14 orphan-book deals; AIB's FY25 cost-income ratio rose four points on defensive investment, the leading indicator of how Dublin will respond.
My view — the live evidence tilts bullish, but the entry leaves no cushion. The Q2/Q3 2026 RoTCE print on a clean base is the binary signal that resolves the wait.

Watchlist to re-rate: 1) H1 2026 RoTCE on clean post-Knab/Barclays base on 22 July. 2) Cumulative deposit beta versus the 35% Q1 print. 3) PTSB Day-1 pro-forma cost-income ratio at close.